Results 1 to 10 of about 106,967 (273)

Acceptance of a malaria vaccine among caregivers of sick children under 5 years of age in Burundi [PDF]

Malaria Journal
Background Malaria poses a significant public health burden globally, particularly in Burundi, where it is the leading cause of mortality and morbidity. To eliminate malaria, the malaria vaccine will be introduced in childhood vaccination.
Eric Ntihebuwayo, Manassé Nimpagaritse, Thomas Bizimana, Stany Banzimana, Dieudonné Kabura, Pierre Sinarinzi, Domina Asingizwe   +6 more
doaj   +2 more sources

Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine

Nature Communications, 2022
In this phase 2 clinical trial, the authors assess protective efficacy of a Plasmodium vivax circumsporozoite vaccine in naïve and semi-immune individuals from controlled human malaria infection as well as antibody and IFN-γ response to vaccination.
Myriam Arévalo-Herrera, Xiomara Gaitán, Michelle Larmat-Delgado, María Alejandra Caicedo, Sonia M. Herrera, Juliana Henao-Giraldo, Angélica Castellanos, Jean-Christophe Devaud, André Pannatier, José Oñate, Giampietro Corradin, Sócrates Herrera   +11 more
doaj   +1 more source

POST introduction evaluation (PIE) of the malaria vaccine introduced in three pilot countries (Ghana, Kenya, and Malawi) in 2021. [PDF]

Malar J
Walldorf JA, Mayers GF, Amponsa-Achiano K, Jalang'o R, Chisema M, Khalayi L, Njoroge J, Haji A, Tweneboah PO, Sally ET, Mategula D, Mhone B, Zimba B, Chirwa E, Mohammed NT, Adjei MR, Sillah J, Pellaux-Furrer E, Magafu MGMD, Okine RNA.   +19 more
europepmc   +3 more sources

Genetic disruption of Plasmodium falciparum Merozoite surface antigen 180 (PfMSA180) suggests an essential role during parasite egress from erythrocytes

Scientific Reports, 2021
Plasmodium falciparum, the parasite responsible for severe malaria, develops within erythrocytes. Merozoite invasion and subsequent egress of intraerythrocytic parasites are essential for this erythrocytic cycle, parasite survival and pathogenesis.
Vanndita Bahl, Kritika Chaddha, Syed Yusuf Mian, Anthony A. Holder, Ellen Knuepfer, Deepak Gaur   +5 more
doaj   +1 more source

Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers

Human Vaccines & Immunotherapeutics, 2020
Introduction: RTS,S/AS01 is currently the most advanced malaria vaccine but provides incomplete, short-term protection. It was developed for use within the expanded program on immunizations (EPI) for African children. Another use could be adding mass RTS,
Lorenz von Seidlein, Borimas Hanboonkunupakarn, Podjanee Jittamala, Pongphaya Pongsuwan, Kesinee Chotivanich, Joel Tarning, Richard M. Hoglund, Markus Winterberg, Mavuto Mukaka, Pimnara Peerawaranun, Pasathorn Sirithiranont, Zoe Doran, Christian F. Ockenhouse, Karen Ivinson, Cynthia Lee, Ashley J. Birkett, David C. Kaslow, Pratap Singhasivanon, Nicholas P.J. Day, Arjen M. Dondorp, Nicholas J. White, Sasithon Pukrittayakamee   +21 more
doaj   +1 more source

Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection

npj Vaccines, 2021
RTS,S/AS01 is an advanced pre-erythrocytic malaria vaccine candidate with demonstrated vaccine efficacy up to 86.7% in controlled human malaria infection (CHMI) studies; however, reproducible immune correlates of protection (CoP) are elusive. To identify
Kelly E. Seaton, Rachel L. Spreng, Milite Abraha, Matthew Reichartz, Michelle Rojas, Frederick Feely, Richard H. C. Huntwork, Sheetij Dutta, Sarah V. Mudrak, S. Munir Alam, Scott Gregory, Erik Jongert, Margherita Coccia, Fernando Ulloa-Montoya, Ulrike Wille-Reece, Georgia D. Tomaras, S. Moses Dennison   +16 more
doaj   +1 more source

Community perceptions of a malaria vaccine in the Kintampo districts of Ghana. [PDF]

, 2013
BACKGROUND: Malaria remains the leading cause of morbidity and mortality in sub-Saharan Africa despite tools currently available for its control. Making malaria vaccine available for routine use will be a major hallmark, but its acceptance by community ...
A Bingham, A Dodoo, A Launiala, A Olotu, AK Rowe, AS Jegede, C Wongsrichanalai, CA Baume, CA de Quadros, Dan-Bright S Dzorgbo, DB Dery, DI Ojakaa, E Klinkenberg, F Nuwaha, FN Binka, G GSS, Kojo A Senah, KP Asante, Kwaku P Asante, Lawrence G Febir, PW Chung, RW Snow, S Owusu-Agyei, S Owusu-Agyei, S Owusu-Agyei, Seth Owusu-Agyei, ST Agnandji, ST Agnandji, TE Nkya, Timothy S Letsa, WHO   +30 more
core   +2 more sources

Novel ELISA method as exploratory tool to assess immunity induced by radiated attenuated sporozoites to decipher protective immunity

Malaria Journal, 2017
Background Whole parasite vaccines provide a unique opportunity for dissecting immune mechanisms and identify antigens that are targeted by immune responses which have the potential to mediate sterile protection against malaria infections.
Trey A. Knepper, Elizabeth H. Duncan, Tatyana Savransky, Elke S. Bergmann-Leitner   +3 more
doaj   +1 more source

Revealing the molecular signatures of host-pathogen interactions. [PDF]

, 2011
Advances in sequencing technology and genome-wide association studies are now revealing the complex interactions between hosts and pathogen through genomic variation signatures, which arise from evolutionary co ...
C Herdtweck, C Loscos, C Sik-Lányi, F Yan, G Xing, GJ Ward, H Kolivand, H Kolivand, Hoshang Kolivand, J Blinn, J Hensley, K Jacobs, K Kaneda, K Kilteni, K Tadamura, KL Wilson, Kolivand, L Hosek, M Aittala, M Haller, M Kanbara, M Knecht, M Slater, M Sunar, Mohd Shahrizal Sunar, MS Sunar, MZ Shao, N Greene, P Debevec, R Azuma, R Ji, R Ji, R Kittler, R Kittler, R Kittler, R Klassen, R Perez, RC Yeoh, Rongrong Ji, S Gibson, S Lee, T Annen, T Guan, T Naemura, T Nishita, W Donnelly, W Hartmann, W Reeves, Y Dobashi, Y Dobashi, Y Feng, Y Liu, Y Liu, Z Noh   +53 more
core   +18 more sources

Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein

Malaria Journal, 2020
Background New strategies are needed to reduce the incidence of malaria, and promising approaches include the development of vaccines and monoclonal antibodies (mAbs) that target the circumsporozoite protein (CSP). To select the best candidates and speed
Rama Raghunandan, Bryan T. Mayer, Yevel Flores-Garcia, Monica W. Gerber, Raphael Gottardo, Hugo Jhun, Sonia M. Herrera, Daniel W. Perez-Ramos, Emily Locke, C. Richter King, Fidel Zavala   +10 more
doaj   +1 more source